Vulvar Atrophy: Signs, Causes and Treatment Options

If you’re experiencing vaginal dryness, burning, or painful intercourse, you’re not imagining things, and you’re certainly not alone. Vulvar atrophy is one part of genitourinary syndrome of menopause (GSM), a common condition affecting postmenopausal women, yet many suffer in silence because they believe it’s just part of aging. The truth is simpler: declining estrogen levels cause measurable tissue changes that respond remarkably well to treatment, particularly bioidentical hormone therapy delivered vaginally like Oestra™.

Understanding Vulvar Atrophy: What It Is and Why It Happens

The Modern Medical Term: Genitourinary Syndrome of Menopause

Medical professionals now use the term Genitourinary Syndrome of Menopause (GSM) to describe what was previously called vulvovaginal atrophy or atrophic vaginitis. This terminology change, adopted by The Menopause Society in 2014, better reflects how the condition affects multiple systems: your vagina, vulva, urethra, and bladder.

The name change matters because it removes stigma and acknowledges that GSM isn’t just a vaginal problem. It’s a response to declining hormone levels that affects your vaginal and vulvar tissues, urinary tract, sexual function, and daily comfort.

The Role of Estrogen in Vaginal Health

Estrogen maintains the health, thickness, and elasticity of vaginal and vulvar tissues. When estrogen levels decline during perimenopause and menopause, these tissues undergo measurable changes:

• Vaginal walls become thinner and less elastic
• Natural lubrication decreases significantly
• Vaginal pH rises from a protective acidic range (3.8-4.5) to above 5.0
• Blood flow to genital tissues diminishes
• The vaginal canal may shorten and narrow

These changes are progressive, meaning they worsen over time without treatment. Unlike vasomotor symptoms such as hot flashes that often resolve naturally, GSM continues advancing throughout the postmenopausal years.

Common Conditions Leading to Vulvar Atrophy

While natural menopause is the most common cause, any condition that reduces estrogen can trigger vulvar atrophy.

Surgical menopause from bilateral oophorectomy creates immediate, often severe symptoms because estrogen production stops abruptly rather than declining gradually.

Cancer treatments including chemotherapy, radiation therapy, and hormone-blocking medications like aromatase inhibitors frequently cause significant vulvar atrophy. Women on breast cancer treatment experience some of the most challenging symptoms.

Other hormonal conditions such as primary ovarian insufficiency and hypothalamic amenorrhea can reduce estrogen levels and cause similar vulvovaginal tissue changes. These conditions require individualized evaluation to identify and address the underlying hormonal deficiency.

Postpartum and breastfeeding create temporary hypoestrogenic states that may cause symptoms similar to menopause, though these typically resolve once breastfeeding ends.

Recognizing the Signs: What Does Vaginal Atrophy Look Like?

Physical Symptoms You May Experience

The hallmark symptom is vaginal dryness, reported by approximately 75% of affected women.

But symptoms extend far beyond dryness.

Genital symptoms include:

• Persistent vaginal dryness, itching, or burning
• Irritation, soreness, or general discomfort
• Pain or bleeding during or after intercourse (dyspareunia)
• Vaginal discharge changes
• Feeling of vaginal tightness or narrowing

Urinary symptoms include:

• Increased urgency and frequency
• Painful urination (dysuria)
• Recurrent urinary tract infections
• Stress or urgency incontinence
• Waking at night to urinate

Visual Cues of Atrophy

During examination, healthcare providers may observe several physical signs:

• Loss of labial fullness
• Vulvar pallor or paleness
• Smooth and shiny vaginal walls (loss of natural folds called rugae)
• Tissue that appears thin or fragile
• Small tears or fissures, particularly near the vaginal opening

The loss of vaginal rugae, those natural folds in healthy vaginal tissue, represents one of the clearest physical signs of estrogen decline. These folds provide elasticity during intercourse, and without them, tissue becomes fragile and prone to tearing.

When to Seek Medical Advice for Bleeding

Postmenopausal bleeding always warrants medical evaluation. While GSM can cause bleeding from fragile tissues during intercourse, bleeding may also indicate other conditions requiring attention.

Contact your healthcare provider if you experience:

• Any bleeding after menopause (you haven’t had a period for 12+ months)
• New spotting or bleeding after intercourse, even if it occurs only once or stops on its own
• Persistent unusual discharge
• Pelvic pain or pressure

Exploring the Causes of Vaginal Atrophy

Hormonal Changes Across Life Stages

Estrogen decline begins earlier than most women realize. Perimenopause symptoms can start in your late 30s or early 40s, with hormone fluctuations causing the first signs of tissue changes years before menopause.

The average age of natural menopause is 51, but the hormonal transition typically lasts around 4-6 years and can vary considerably between women. During this time, estrogen levels fluctuate unpredictably before their final decline, explaining why symptoms may come and go before becoming constant.

After menopause, estrogen production decreases by approximately 90%. The tissues that relied on estrogen for maintenance, including vaginal, vulvar, and urethral tissues, begin their progressive decline without hormonal support.

Medical Treatments and Lifestyle Factors

Certain medications and treatments accelerate or worsen vulvar atrophy.

Aromatase inhibitors used in breast cancer treatment block estrogen production throughout the body, causing particularly severe GSM symptoms. Studies show breast cancer survivors on these medications experience some of the highest rates of vulvar atrophy.

GnRH agonists and antagonists prescribed for endometriosis or fibroids create a temporary menopausal state that can trigger symptoms.

Smoking decreases blood flow and oxygen delivery to vaginal tissues, accelerating atrophy and making symptoms more severe. Women who smoke experience vulvar atrophy at higher rates and with greater severity than non-smokers.

Sexual inactivity may contribute to worsening symptoms. Regular sexual activity (with or without a partner) helps maintain blood flow and tissue elasticity.

Effective Vaginal Moisturizers for Comfort and Relief

Over-the-Counter Solutions for Dryness

For women with mild symptoms, or as a complement to other treatments, vaginal moisturizers provide meaningful relief. Unlike lubricants used only during sexual activity, moisturizers are applied regularly (typically 2-3 times weekly) to maintain ongoing tissue hydration.

How moisturizers work: These products contain hygroscopic ingredients that attract and retain water within vaginal tissues, providing sustained moisture independent of sexual activity.

Effective ingredients to look for:

• Hyaluronic acid (excellent moisture retention)
• Polycarbophil-based formulas
• Glycerin-free options for sensitive tissues

Studies comparing vaginal moisturizers to low-dose estrogen show similar improvement for mild symptoms over 12 weeks. However, moisturizers cannot restore tissue thickness or reverse the underlying hormonal cause of atrophy.

Choosing the Right Moisturizer for You

Choosing gentle, vaginal-safe products can help minimize irritation, particularly when tissues are already sensitive. Look for formulas designed for vaginal use, ideally without added fragrances or warming agents.

Glycerin and parabens do not automatically make a product unsafe, although individual sensitivities vary. For persistent discomfort, vaginal estrogen therapy addresses estrogen-related tissue changes more directly than moisturizers alone.

Vaginal Estrogen Cream: Benefits and Considerations

How Vaginal Estrogen Cream Works

Low-dose vaginal estrogen represents the most effective treatment for moderate to severe vulvar atrophy. When applied directly to vaginal tissues, estrogen:

• Restores vaginal epithelial thickness
• Returns vaginal pH to its protective acidic range
• Increases natural lubrication
• Improves blood flow to genital tissues
• Rebuilds collagen and elasticity

The vaginal route offers a critical advantage: direct tissue targeting. Rather than traveling through your digestive system and liver like oral hormones, vaginal estrogen delivers medication exactly where it’s needed. The vaginal route supports both local absorption and, depending on the dose, systemic hormone delivery. The first uterine pass effect specifically describes how certain vaginal formulations can deliver higher hormone concentrations to the uterus.

Oestra™ combines bioidentical estradiol with progesterone in a vaginal cream formulation, addressing both local symptoms and systemic hormone balance. Inner Balance describes an approximately 4x bioavailability advantage for vaginal delivery compared with oral hormone therapy. Actual absorption depends on the formulation and dose.

Relief Beyond Dryness: Addressing UTIs

Vaginal estrogen does more than relieve dryness. Research shows that vaginal estrogen can significantly reduce recurrent urinary infections in postmenopausal women, although the degree of protection varies depending on the individual and treatment used.

This protection comes from:

• Restored vaginal pH that supports healthy lactobacilli
• Improved urethral tissue health
• Better vaginal microflora balance

For women experiencing recurrent UTIs, the 2025 AUA/SUFU/AUGS guideline recommends vaginal estrogen to help prevent future infections.

Understanding Side Effects and Safety of Vaginal Estrogen

Potential Mild Side Effects

Most women tolerate vaginal estrogen well. When side effects occur, they’re typically mild and temporary:

• Breast tenderness (usually resolves within 3 months)
• Vaginal discharge
• Light spotting or bleeding, which should be evaluated by a healthcare provider after menopause
• Occasional headache

Mild side effects may improve as your body adjusts to treatment, but any unexplained postmenopausal bleeding requires medical evaluation.

Important Safety Information

Updated safety evidence has improved our understanding of vaginal estrogen therapy. Research on low-dose vaginal estrogen supports its favorable safety profile for treating GSM. However, safety considerations depend on hormone dose, systemic absorption, and individual medical history.

Key safety considerations:

• Low-dose vaginal estrogen generally produces limited systemic absorption, as shown in clinical research
• Studies of low-dose vaginal estrogen have provided reassuring safety findings, although long-term risks still require individualized consideration
• Progestogen is generally not required with low-dose local vaginal estrogen, but systemic estrogen therapy requires appropriate endometrial protection in women with a uterus
• Oestra™ differs from local-only treatments because its combined estradiol and progesterone formulation is designed for systemic hormone support. Its safety and dosing should be evaluated separately from standard low-dose GSM products

For breast cancer survivors: Research on low-dose vaginal estrogen has provided reassuring findings for certain women experiencing persistent GSM symptoms. However, treatment decisions should be individualized, particularly for women taking tamoxifen or aromatase inhibitors. These patients should consult their oncology team before starting vaginal hormone therapy. Safety findings from low-dose local estrogen treatments should not automatically be applied to systemic hormone formulations.

Vaginal Estrogen Tablets and Other Delivery Methods

Comparing Tablets, Creams, and Rings

Multiple vaginal estrogen formulations exist, each with advantages.

Creams offer flexibility in dosing, and certain formulations can be applied to external vulvar tissues for targeted relief. Oestra™ differs from standard low-dose vaginal estrogen creams because it combines bioidentical estradiol and progesterone for both local and systemic hormone support. Its application and dosing should follow the prescribing clinician’s instructions.

Tablets and inserts provide premeasured doses and less messiness. Some require applicators, while others can be inserted by hand. However, they offer less flexibility for treating external vulvar symptoms directly.

Rings offer convenience, releasing estrogen continuously for 90 days. Some women prefer the set and forget approach, though rings may shift or be felt during intercourse.

Choosing the Best Method for Your Needs

The right choice depends on your symptoms, preferences, and lifestyle:

• External vulvar symptoms: Creams allow direct application to affected areas
• Convenience priority: Rings require attention only every three months
• Dose flexibility: Creams permit adjustments based on symptom response
• Messiness concerns: Tablets or rings may feel cleaner

Inner Balance’s approach emphasizes vaginal delivery because it allows efficient hormone absorption while bypassing first-pass liver metabolism. Unlike oral pills, vaginal formulations avoid initial processing through the digestive system and liver. Patches and gels also bypass first-pass metabolism, but vaginal delivery offers the additional advantage of direct exposure to vaginal tissues alongside potential systemic hormone support.

Beyond Estrogen: Holistic Approaches to Vulvar Atrophy

Lifestyle Modifications for Vaginal Health

Complementary strategies support hormone therapy and provide additional relief.

Regular sexual activity maintains blood flow to genital tissues and preserves elasticity. This includes partnered activity and solo stimulation.

Gentle vulvar care protects already-sensitive tissues:

• Wash with plain water or gentle, fragrance-free cleansers
• Avoid douching (disrupts protective vaginal bacteria)
• Choose cotton underwear and avoid tight clothing
• Use fragrance-free laundry detergent

Smoking cessation improves blood flow to all tissues, including genital areas.

Adequate hydration supports overall tissue moisture.

Complementary Therapies for Symptom Management

Pelvic floor physical therapy helps women with pelvic floor dysfunction, hypertonic muscles, or persistent pain. Research shows 12 weeks of pelvic floor muscle training improved GSM symptoms and increased vaginal secretions.

Vaginal dilators gradually stretch narrowed tissues. Used with lubricant and sometimes combined with pelvic floor therapy, dilators can reverse introital stenosis (narrowing of the vaginal opening).

For women seeking comprehensive support, Inner Balance offers curated supplement protocols through their Fullscript partnership, providing 20% discounts on physician-selected supplements designed to complement hormone therapy.

Inner Balance: A Modern Approach to Hormonal Health for Women

Why Inner Balance Stands Apart

Inner Balance was founded by Dr. Sarah Daccarett, MD, a board-certified physician specializing in women’s hormonal health and longevity medicine, on a simple principle: women deserve to be believed by their doctors.

The company’s flagship product, Oestra™ Hormone Cream, delivers bioidentical estradiol and progesterone through vaginal application, addressing both local symptoms and systemic hormone balance in one comprehensive treatment.

Key advantages include:

• Vaginal delivery achieving 4x better bioavailability than oral forms
• Combined estradiol and progesterone in one product
• Symptom-based treatment guided by medical history, clinical evaluation, and appropriate testing
• Telehealth consultations with board-certified physicians
• Licensed medical practice in all 50 states

Tailored Solutions for Perimenopause and Menopause

Inner Balance recognizes that hormone decline begins years before traditional menopause. Women in their 30s and 40s experiencing early symptoms deserve treatment, not dismissal.

The comprehensive approach addresses the root cause of vulvar atrophy: hormone imbalance. Rather than managing symptoms with moisturizers alone, bioidentical hormone therapy restores what’s missing, providing tissue restoration that non-hormonal approaches cannot achieve.

For women experiencing low libido alongside vulvar atrophy, Inner Balance also offers Libida™, a targeted solution addressing desire through brain-based pathways. For hormone-related skin aging, BodyMatched™ Anti-Aging Cream provides prescription-strength topical support with bioidentical estriol.

Inner Balance data shows 97% of women report improvement in vaginal dryness with consistent Oestra™ use. This reflects real-world results from women who’ve struggled with vulvar atrophy and found effective relief through comprehensive hormone therapy.

Frequently Asked Questions

What is the difference between vaginal dryness and vulvar atrophy?

Vaginal dryness is a symptom, while vulvar atrophy refers to thinning and other changes in the external vulvar tissues caused by declining estrogen. Both can occur as part of GSM, and they often share the same hormonal cause. Treating only dryness with lubricants addresses the symptom without reversing the tissue deterioration. Effective treatment targets the underlying atrophy itself.

Can vulvar atrophy improve without hormone therapy?

Mild symptoms may be managed with moisturizers and lubricants, but the tissue changes themselves are progressive without estrogen. Unlike hot flashes that may resolve naturally, vulvar atrophy continues worsening throughout the postmenopausal years. Non-hormonal approaches provide symptom relief but cannot restore tissue thickness, pH balance, or natural lubrication the way estrogen can. Hormone therapy remains the most effective treatment for reversing underlying tissue changes.

Is vaginal estrogen cream safe for long-term use?

Low-dose vaginal estrogen is an effective long-term treatment option for many women with GSM. Clinical evidence shows that systemic absorption is generally low with these formulations, and added progesterone is usually unnecessary. However, systemic hormone treatments such as Oestra™ have different dosing and safety considerations. A healthcare provider can help determine the most appropriate long-term approach based on your symptoms, medical history, and treatment goals.

How quickly can I expect to see results from vaginal atrophy treatment?

Most women notice initial improvement within 2-4 weeks of starting vaginal estrogen, with maximal benefit occurring around 12 weeks. Symptoms like dryness and irritation often improve first, followed by gradual tissue restoration. Inner Balance data shows 97% of women report improvement in vaginal dryness with consistent use. The timeline varies based on symptom severity and treatment compliance.

Can vulvar atrophy affect sexual desire?

Yes, though the relationship is complex. Physical discomfort from atrophy, including pain, dryness, and reduced sensation, often leads to decreased interest in intimacy. Some women experience reduced arousal and difficulty with orgasm as tissue sensitivity changes. Treating the underlying atrophy frequently improves sexual comfort and, indirectly, desire. For women whose desire remains low even after addressing physical symptoms, targeted libido support may provide additional benefit.